Cargando…

Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry

BACKGROUND AND OBJECTIVE: The optimal timing for initiation of dabigatran after acute ischaemic stroke (AIS) is not established. We aimed to evaluate initiation timing and clinical outcomes of dabigatran in AIS patients with non-valvular atrial fibrillation (NVAF). DESIGN: Retrospective study based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escudero-Martinez, Irene, Mazya, Michael, Teutsch, Christine, Lesko, Norbert, Gdovinova, Zuzana, Barbarini, Leonardo, Fryze, Waldemar, Karlinski, Michal, Kobayashi, Adam, Krastev, Georgi, Paiva Nunes, Ana, Pasztoova, Katarina, Peeters, André, Sobolewski, Piotr, Vilionskis, Aleksandras, Toni, Danilo, Ahmed, Niaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247395/ https://www.ncbi.nlm.nih.gov/pubmed/32434935 http://dx.doi.org/10.1136/bmjopen-2020-037234

Ejemplares similares

Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020)

Editorial: Quality of stroke care: what could be improved, and how?
por: Vilionskis, Aleksandras, et al.
Publicado: (2023)

Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry
por: Dubner, Sergio, et al.
Publicado: (2020)

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
por: Huisman, Menno V., et al.
Publicado: (2022)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

Association between systolic blood pressure parameters and unexplained early neurological deterioration (UnND) in acute ischemic stroke patients treated with mechanical thrombectomy
por: Vilionskis, Aleksandras, et al.
Publicado: (2022)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement
por: Ioannou, Adam, et al.
Publicado: (2016)

Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
por: Kuwayama, Tasuku, et al.
Publicado: (2017)

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
por: Zhu, Zhu, et al.
Publicado: (2022)

Applying openEHR’s Guideline Definition Language to the SITS international stroke treatment registry: a European retrospective observational study
por: Anani, Nadim, et al.
Publicado: (2017)

Cerebral Edema in Patients with severe Hemispheric Syndrome: Incidence, Risk Factors, and Outcomes—Data from SITS-ISTR
por: Escudero-Martínez, Irene, et al.
Publicado: (2023)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial
por: Yu, Yi-bo, et al.
Publicado: (2018)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

The impact of a comprehensive national policy on improving acute stroke patient care in Lithuania
por: Masiliūnas, Rytis, et al.
Publicado: (2022)

Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program
por: Azar, Rabih R., et al.
Publicado: (2021)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol
por: Iturbe-Hernandez, Teodoro, et al.
Publicado: (2020)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
por: Pink, Joshua, et al.
Publicado: (2011)

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
por: Vene, Nina, et al.
Publicado: (2016)

Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study
por: Lauffenburger, Julie C., et al.
Publicado: (2015)

Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
por: Zhou, Wei, et al.
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

The Physical Activity Levels and Sitting Time of Adults Living With Atrial Fibrillation: The CHAMPLAIN-AF Study
por: Way, Kimberley L., et al.
Publicado: (2022)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
por: Kafke, Waldemar, et al.
Publicado: (2016)

A case report of recurrent transient ischaemic attacks on dabigatran for atrial fibrillation: real-world insight into treatment failure
por: Huynh, Ronald, et al.
Publicado: (2020)

The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Association between body mass index and the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran: a cohort study
por: Li, Ming-Hui, et al.
Publicado: (2020)

Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran
por: Huang, Yung-Chuan, et al.
Publicado: (2023)

Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF
por: Kodani, Eitaro, et al.
Publicado: (2022)

Prehospital Stroke Care, Paramedic Training Needs, and Hospital-Directed Feedback in Lithuania
por: Melaika, Kazimieras, et al.
Publicado: (2022)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran and apolipoprotein B
por: ten Cate, Hugo
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sopp4dh3facnt035sof2i4pf95